Breaking News Instant updates and real-time market news.

CATB

Catabasis Pharmaceuticals

$5.79

-0.37 (-6.01%)

08:05
10/04/16
10/04
08:05
10/04/16
08:05

Catabasis reaches target enrollment for Part B of MoveDMD trial

Catabasis Pharmaceuticals announced that target enrollment of 30 patients has been reached for Part B of the MoveDMD trial, a 12-week trial to assess the safety and efficacy of edasalonexent, CAT-1004, in Duchenne muscular dystrophy. Edasalonexent is an oral small molecule that the Company believes has the potential to be a disease-modifying therapy for DMD patients, regardless of their underlying dystrophin mutation. Catabasis has previously reported positive safety, tolerability, pharmacokinetics and biomarker results from Part A of the trial. Based on scheduling of the enrolled patients as of September 30, 2016, the Company expects to report top-line safety and efficacy results from this Phase 2 trial in the first half of Q1 2017. In the first portion of the MoveDMD trial (Part A), 17 ambulatory boys between ages 4 and 7 with a genetically confirmed diagnosis of DMD across a range of dystrophin mutations received edasalonexent. The boys were steroid naive or had not used steroids for at least six months prior to the trial. This portion of the trial was conducted at three sites in the U.S., and assessed the safety, tolerability and pharmacokinetics of edasalonexent in patients at three dosing levels during seven days of dosing. Sixteen of the boys who participated in the first part of the MoveDMD trial are participating in Part B. Phase 2 of the MoveDMD trial is a randomized, double-blind, placebo-controlled trial of approximately 30 boys to evaluate the safety and efficacy of edasalonexent in DMD over a 12-week period at five clinical trial sites in the U.S. at two dosing levels, 67 mg/kg/day and 100 mg/kg/day. The open-label extension was initiated in July and includes dosing with edasalonexent for 36 weeks beyond the 12-week placebo-controlled portion of the trial and will evaluate longer term safety and efficacy with the same clinical end points. PPMD and the Muscular Dystrophy Association are providing funding to support participant travel for the MoveDMD trial.

CATB Catabasis Pharmaceuticals
$5.79

-0.37 (-6.01%)

12/10/15
WEDB
12/10/15
NO CHANGE
Target $27
WEDB
Outperform
Catabasis results could lead to partnership discussions, says Wedbush
Wedbush analyst Liana Moussatos said Catabsis announced the initiation of its Phase 2a trial of CAT-2054, its orally available SREBP inhibitor, in patients with hypercholesterolemia. Moussatos believes results from this trial could provide a basis for partnering discussions with a Big Pharma company with a presence in the metabolic space. The analyst sees potential peak worldwide sales of over $5.7B, and a partnering deal could have a lucrative upfront payment as well as significant milestones and royalties. Moussatos rates Catabasis an Outperform with a $27 price target on shares.
04/08/16
SBSH
04/08/16
NO CHANGE
SBSH
Citi lays out potential targets after break of Pfizer, Allergan deal
Citi analysts Yigal Nochomovitz, Liav Abraham and Joel Beatty argue that the break of the Pfizer (PFE), Allergan (AGN) merger could accelerate smaller scale acquisitions in the Biotechnology sector. The implication that larger companies could accelerate M&A activity to bolster pipelines in lieu of the mega-merger pathway aided shares in the sector this week, the analysts contend in a research note. They now believe that Ardelyx (ARDX), Medivation (MDVN), Ophthotech (OPHT), Puma Biotechnology (PBYI), Portola Pharmaceuticals (PTLA), Ultragenyx (RARE), Relypsa (RLYP) and Versartis (VSAR) have a greater probability of being acquired in the next 12-18 months. Beside these favored names for a takeover, analyst Joel Beatty sees a greater chance of Catabasis Pharmaceuticals (CATB), Intercept Pharmaceuticals (ICPT), Novavax (NVAX) and Raptor Pharmaceuticals (RPTP) getting acquired over the next 18 months.
06/08/16
COWN
06/08/16
NO CHANGE
Target $30
COWN
Outperform
Catabasis Pharmaceuticals DMD drug potential undervalued, says Cowen
Cowen noted Catabasis Pharmaceuticals halted its Phase-2 trial for CAT-2054 as it did not meet its primary endpoint in reducing LDL in hypercholesterolemia. Cowen, however, feels the shares are undervalued based on the potential of its edasalonexent drug candidate for Duchenne muscular dystropy, or DMD. The firm said the drug has the potential to be effective in all DMD patients regardless of the patient's underlying dystrophin mutation. Cowen maintained its Outperform rating and $30 price target on Catabasis shares.
06/09/16
SBSH
06/09/16
NO CHANGE
Target $8
SBSH
Buy
Catabasis Pharmaceuticals price target lowered to $8 from $16 at Citi
Citi analyst Joel Beatty halved his price target for Catabasis Pharmaceuticals to $8 and removed CAT-2054 from his model after the agent failed to lower cholesterol on top of statins in a Phase 2 trial. The analyst, however, continues to see favorable risk/reward into Phase 2 data in late 2016 for lead agent CAT-1004 in Duchenne Muscular Dystrophy. Beatty keeps a Buy rating on Catabasis.

TODAY'S FREE FLY STORIES

FND

Floor & Decor Holdings

20:03
04/26/17
04/26
20:03
04/26/17
20:03
Syndicate
Floor & Decor Holdings 8.824M share IPO priced at $21.00 »

The deal priced above the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

SNE

Sony

$33.58

-0.07 (-0.21%)

, FOX

21st Century Fox

$30.05

0.16 (0.54%)

20:02
04/26/17
04/26
20:02
04/26/17
20:02
Periodicals
Sony narrows search for studio boss to Vinciquerra, WSJ says »

Former Fox (FOX) TV head…

SNE

Sony

$33.58

-0.07 (-0.21%)

FOX

21st Century Fox

$30.05

0.16 (0.54%)

FOXA

21st Century Fox

$30.74

0.13 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 10

    May

  • 24

    May

  • 25

    May

  • 15

    Jun

VZ

Verizon

$47.36

0.66 (1.41%)

19:57
04/26/17
04/26
19:57
04/26/17
19:57
Periodicals
Verizon go90 boss departs, Business Insider says »

Verizon go90 chief Chip…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

SSNLF

Samsung

19:45
04/26/17
04/26
19:45
04/26/17
19:45
Hot Stocks
Samsung sees FY17 earnings growth, cites health in memory, OLED »

"Moving on to the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

19:42
04/26/17
04/26
19:42
04/26/17
19:42
Hot Stocks
Samsung sees Q2 growth due to 'robust' memory performance, Galaxy S8 launch »

"Looking ahead to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

19:40
04/26/17
04/26
19:40
04/26/17
19:40
Earnings
Samsung reports Q1 operating profit 9.9T won vs. 6.68T won last year »

Reports Q1 revenue 50.55T…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADM

Archer Daniels

$45.27

-0.31 (-0.68%)

19:36
04/26/17
04/26
19:36
04/26/17
19:36
Periodicals
Archer Daniels appoints new head of global trading desk, Reuters says »

Archer Daniels has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

FTI

TechnipFMC

$32.26

0.14 (0.44%)

19:35
04/26/17
04/26
19:35
04/26/17
19:35
Earnings
TechnipFMC reports Q1 adjusted EPS 71c, consensus 33c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 01

    May

F

Ford

$11.60

0.12 (1.05%)

, GM

General Motors

$34.38

0.39 (1.15%)

19:29
04/26/17
04/26
19:29
04/26/17
19:29
Periodicals
Transportation, EPA chiefs to meet with major automakers, Reuters says »

Transportation Secretary…

F

Ford

$11.60

0.12 (1.05%)

GM

General Motors

$34.38

0.39 (1.15%)

TM

Toyota

$109.91

1.19 (1.09%)

VLKAY

Volkswagen

$32.13

-0.2 (-0.62%)

FCAU

Fiat Chrysler

$11.65

1.11 (10.53%)

DDAIF

Daimler AG

$74.57

-0.6001 (-0.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

  • 02

    May

CMCSA

Comcast

$38.79

0.3 (0.78%)

, CMCSK

Comcast

19:24
04/26/17
04/26
19:24
04/26/17
19:24
Hot Stocks
Comcast responds to FCC net neutrality news, says committed to open Internet »

Responding to FCC…

CMCSA

Comcast

$38.79

0.3 (0.78%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

PCH

Potlatch

$46.50

1.25 (2.76%)

19:18
04/26/17
04/26
19:18
04/26/17
19:18
Earnings
Potlatch reports Q1 EPS 41c, consensus 20c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

DBOEY

Deutsche Boerse

$9.59

-0.005 (-0.05%)

19:13
04/26/17
04/26
19:13
04/26/17
19:13
Hot Stocks
Deutsche Boerse says plans EUR 200M repurchase program »

Deutsche Boerse announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBLI

Cleveland BioLabs

$3.64

-0.11 (-2.93%)

19:03
04/26/17
04/26
19:03
04/26/17
19:03
Hot Stocks
Cleveland BioLabs names John Szydlo principal financial officer »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SU

Suncor

$30.62

-0.53 (-1.70%)

19:02
04/26/17
04/26
19:02
04/26/17
19:02
Hot Stocks
Suncor to repurchase up to C$2B of company's shares through NCIB »

Suncor announced plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

NBR

Nabors Industries

$11.74

-0.03 (-0.25%)

18:53
04/26/17
04/26
18:53
04/26/17
18:53
Earnings
Nabors Industries reports Q1 cont-op EPS with item (52c), consensus (35c) »

Reports Q1 revenue $563M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 01

    May

RTN

Raytheon

$155.27

-0.74 (-0.47%)

18:40
04/26/17
04/26
18:40
04/26/17
18:40
Hot Stocks
Raytheon awarded $375M U.S. Air Force contract »

The U.S. Air Force…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

NOV

National Oilwell

$36.15

0.33 (0.92%)

18:38
04/26/17
04/26
18:38
04/26/17
18:38
Hot Stocks
National Oilwell reports Q1 book-to-bill of 41% for Rig Systems »

Backlog for capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 01

    May

  • 01

    May

OIS

Oil States

$32.10

-0.3 (-0.93%)

18:36
04/26/17
04/26
18:36
04/26/17
18:36
Earnings
Oil States reports Q1 adjusted EPS (34c), consensus (27c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 01

    May

PSA

Public Storage

$223.93

-1.61 (-0.71%)

18:35
04/26/17
04/26
18:35
04/26/17
18:35
Earnings
Public Storage reports Q1 core FFO $2.37, consensus $1.65 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

NOV

National Oilwell

$36.15

0.33 (0.92%)

18:31
04/26/17
04/26
18:31
04/26/17
18:31
Earnings
National Oilwell reports Q1 adjusted EPS (17c), consensus (21c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 01

    May

  • 01

    May

PUB

People's Utah Bancorp

$27.55

-0.2 (-0.72%)

18:25
04/26/17
04/26
18:25
04/26/17
18:25
Hot Stocks
People's Utah Bancorp announces CEO succession in 2018 »

People's Utah…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 17

    May

BSFT

BroadSoft

$38.70

0.45 (1.18%)

18:17
04/26/17
04/26
18:17
04/26/17
18:17
Hot Stocks
BroadSoft announces agreement with Telstra for Australia communications »

BroadSoft announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

RJF

Raymond James

$75.74

0.55 (0.73%)

18:14
04/26/17
04/26
18:14
04/26/17
18:14
Earnings
Raymond James reports Q2 adjusted EPS $1.28, consensus $1.14 »

Reports Q2 GAAP EPS 77c.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCTT

Ultra Clean

$17.51

-0.2 (-1.13%)

, TER

Teradyne

$33.77

0.21 (0.63%)

18:14
04/26/17
04/26
18:14
04/26/17
18:14
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Ultra…

UCTT

Ultra Clean

$17.51

-0.2 (-1.13%)

TER

Teradyne

$33.77

0.21 (0.63%)

CRY

CryoLife

$16.75

0.5 (3.08%)

ALSN

Allison Transmission

$37.47

0.53 (1.43%)

MKSI

MKS Instruments

$75.35

0.95 (1.28%)

AXTI

AXT, Inc.

$6.15

-0.25 (-3.91%)

PYPL

PayPal

$44.41

-0.3 (-0.67%)

GGG

Graco

$99.80

1.45 (1.47%)

NOW

ServiceNow

$90.92

0.68 (0.75%)

XLNX

Xilinx

$59.99

-0.7 (-1.15%)

WPG

Washington Prime

$8.92

-0.09 (-1.00%)

MMLP

Martin Midstream Partners

$19.55

-0.15 (-0.76%)

CAVM

Cavium

$70.93

-0.31 (-0.44%)

WLL

Whiting Petroleum

$8.07

-0.22 (-2.65%)

ROG

Rogers Corporation

$92.47

3.23 (3.62%)

INTU

Intuit

$115.81

-3.27 (-2.75%)

WTW

Weight Watchers

$20.16

1.33 (7.06%)

HRB

H&R Block

$23.89

-0.35 (-1.44%)

MLNX

Mellanox

$50.90

-0.05 (-0.10%)

FFIV

F5 Networks

$137.30

-0.89 (-0.64%)

CMPR

Cimpress

$86.25

-0.07 (-0.08%)

CTXS

Citrix

$84.12

0.07 (0.08%)

NTGR

Netgear

$51.35

-1.55 (-2.93%)

ETH

Ethan Allen

$31.25

0.15 (0.48%)

AMGN

Amgen

$164.61

-0.09 (-0.05%)

KN

Knowles

$19.59

0.04 (0.20%)

BWLD

Buffalo Wild Wings

$162.40

-0.4 (-0.25%)

ORLY

O'Reilly Automotive

$265.07

1.11 (0.42%)

SAM

Boston Beer

$141.85

-2.45 (-1.70%)

AMSC

AMSC

$7.70

0.3 (4.05%)

SFST

Southern First Bancshares

$33.05

0.25 (0.76%)

BRKL

Brookline Bancorp

$15.95

0.35 (2.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 10

    May

  • 11

    May

  • 16

    May

  • 17

    May

  • 30

    May

  • 31

    May

  • 07

    Jun

  • 12

    Jun

  • 15

    Jun

  • 20

    Jun

  • 21

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

  • 19

    Jul

  • 14

    Aug

  • 27

    Apr

  • 27

    Apr

NWE

NorthWestern

$59.92

-0.23 (-0.38%)

18:13
04/26/17
04/26
18:13
04/26/17
18:13
Earnings
Breaking Earnings news story on NorthWestern »

NorthWestern backs FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 21

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.